Literature DB >> 31955196

Characteristics of Invasive Pneumococcal Disease Caused by Emerging Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in England: A Prospective Observational Cohort Study, 2014-2018.

Zahin Amin-Chowdhury1, Sarah Collins1, Carmen Sheppard2, David Litt2, Norman K Fry1, Nick Andrews3, Shamez N Ladhani1,4.   

Abstract

BACKGROUND: England is experiencing a rapid increase in invasive pneumococcal disease (IPD) caused by serotypes 8, 12F, and 9N; their clinical characteristics and outcomes have not been described.
METHODS: Public Health England conducts national IPD surveillance. Cases due to emerging serotypes were compared with those included in the 13-valent pneumococcal conjugate vaccine (PCV13) and the remaining non-PCV13 serotypes.
RESULTS: There were 21 592 IPD cases during 2014-15 to 2017-18, including 20 108 (93.1%) with serotyped isolates and 17 450 (86.8%) with completed questionnaires. PCV13 serotypes were responsible for 20.1% (n = 4033), while serotype 8 (3881/20 108 [19.3%]), 12F (2365/20 108 [11.8%]), and 9N (1 296/20 108 [6.4%]) were together responsible for 37.5% of cases. Invasive pneumonia was the most common presentation (11 424/16 346 [69.9%]) and, overall, 67.0% (n = 11 033) had an underlying comorbidity. The median age (interquartile range) at IPD due to serotypes 8 (59 [45-72] years) and 12F (56 [41-70] years) was lower than serotype 9N (67 [53-80] years), PCV13 serotypes (68 [52-81] years), and remaining non-PCV13 serotypes (70 [53-82] years). Serotype 9N IPD cases also had higher comorbidity prevalence (748/1087 [68.8%]) compared to serotype 8 (1901/3228 [58.9%]) or 12F (1042/1994 [52.3%]), and higher case fatality (212/1128 [18.8%]) compared to 8.6% (291/3365) or 10.0% (209/2086), respectively.
CONCLUSIONS: Serotypes 8 and 12F were more likely to cause IPD in younger, healthier individuals and less likely to be fatal, while serotype 9N affected older adults with comorbidities and had higher case fatality. © Crown copyright 2020.

Entities:  

Keywords:  conjugate vaccines; emerging serotypes; immunization; outcome; serotype replacement

Year:  2020        PMID: 31955196     DOI: 10.1093/cid/ciaa043

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Pathogen- and Type-Specific Changes in Invasive Bacterial Disease Epidemiology during the First Year of the COVID-19 Pandemic in The Netherlands.

Authors:  Anneke Steens; Mirjam J Knol; Wieke Freudenburg-de Graaf; Hester E de Melker; Arie van der Ende; Nina M van Sorge
Journal:  Microorganisms       Date:  2022-05-05

2.  Molecular characterization and epidemiology of Streptococcus pneumoniae serotype 8 in Denmark.

Authors:  Camilla Bülow Hansen; Kurt Fuursted; Palle Valentiner-Branth; Tine Dalby; Charlotte Sværke Jørgensen; H-C Slotved
Journal:  BMC Infect Dis       Date:  2021-05-05       Impact factor: 3.090

3.  Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe.

Authors:  Germaine Hanquet; Pavla Krizova; Tina Dalby; Shamez N Ladhani; J Pekka Nuorti; Kostas Danis; Jolita Mereckiene; Mirjam J Knol; Brita A Winje; Pilar Ciruela; Sara de Miguel; Maria Eugenia Portillo; Laura MacDonald; Eva Morfeldt; Jana Kozakova; Palle Valentiner-Branth; Norman K Fry; Hanna Rinta-Kokko; Emmanuelle Varon; Mary Corcoran; Arie van der Ende; Didrik F Vestrheim; Carmen Munoz-Almagro; Juan-Carlos Sanz; Jesus Castilla; Andrew Smith; Birgitta Henriques-Normark; Edoardo Colzani; Lucia Pastore-Celentano; Camelia Savulescu
Journal:  Emerg Infect Dis       Date:  2022-01       Impact factor: 6.883

4.  Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains.

Authors:  Jose Manuel Tirado-Vélez; David Carreño; David Sevillano; Luis Alou; José Yuste; Adela G de la Campa
Journal:  Antibiotics (Basel)       Date:  2021-05-13

5.  Streptococcus Pneumoniae septic arthritis in adults in Bristol and Bath, United Kingdom, 2006-2018: a 13-year retrospective observational cohort study.

Authors:  Catherine Hyams; Zahin Amin-Chowdhury; Norman K Fry; Paul North; Adam Finn; Andrew Judge; Shamez N Ladhani; O Martin Williams
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

6.  Invasive Pneumococcal Disease in Adults in Portugal: The Importance of Serotypes 8 and 3 (2015-2018).

Authors:  Catarina Silva-Costa; Joana Gomes-Silva; Inês Teodoro; Mário Ramirez; José Melo-Cristino
Journal:  Microorganisms       Date:  2021-05-08

7.  Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13.

Authors:  A Redin; P Ciruela; M F de Sevilla; F Gomez-Bertomeu; S Gonzalez-Peris; M A Benitez; G Trujillo; A Diaz; E Jou; C Izquierdo; M O Perez-Moreno; F Moraga-Llop; M Olsina; B Vinado; E Sanfeliu; A Garcia; S Gonzalez-di Lauro; J J Garcia-Garcia; A Dominguez; R Sa-Leao; C Muñoz-Almagro
Journal:  Microbiol Spectr       Date:  2021-12-08

8.  Pneumococcal Serotype Identification by Capsular Sequence Typing (CST): A Modified Novel Approach for Serotyping Directly in Clinical Samples.

Authors:  Nektarios Marmaras; Athanasia Xirogianni; Anastasia Papandreou; Efthymia Petinaki; Vana Papaevangelou; Maria Tsolia; Georgina Tzanakaki
Journal:  Diagnostics (Basel)       Date:  2021-12-14

9.  The economic impact of the switch from single- to multi-dose PCV13 vial in Benin.

Authors:  Patrick G Ilboudo; Téné-Alima Essoh; Roch A Houngnihin; Daleb Abdoulaye Alfa; Naomi Dick; Landry Kaucley; Alexis Satoulou-Maleyo
Journal:  BMC Public Health       Date:  2022-01-19       Impact factor: 3.295

10.  Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in Southwest Sweden.

Authors:  Karin Bergman; Tor Härnqvist; Erik Backhaus; Birger Trollfors; Mats S Dahl; Helena Kolberg; Gunilla Ockborn; Rune Andersson; Johanna Karlsson; Åsa Mellgren; Susann Skovbjerg
Journal:  BMC Infect Dis       Date:  2021-08-04       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.